Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMO | Q99835 | 1/20 | 0.49 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.38 |
| ▸ | HPGDS | O60760 | 4/20 | 0.35 |
| ▸ | JAK2 | O60674 | 2/20 | 0.34 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.34 |
| ▸ | JAK1 | P23458 | 1/20 | 0.34 |
| ▸ | JAK3 | P52333 | 1/20 | 0.34 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.34 |
| ▸ | CDK9 | P50750 | 2/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10003710 | 0.91 | SMO (0.52) | SMOCCNT1CDK9 | |
| SCHEMBL10003286 | 0.89 | SMO (0.55) | SMOJAK2NTRK1JAK1JAK3 | |
| SCHEMBL10003509 | 0.88 | SMO (0.50) | SMOHPGDSJAK2JAK1JAK3 | |
| SCHEMBL10004015 | 0.88 | SMO (0.57) | SMOHPGDSJAK2JAK1JAK3 | |
| SCHEMBL10003412 | 0.87 | SMO (0.51) | SMOPDE10AHPGDS | |
| SCHEMBL10003249 | 0.87 | SMO (0.54) | SMOJAK2JAK1JAK3 | |
| SCHEMBL10003287 | 0.87 | SMO (0.52) | SMOJAK2JAK1JAK3 | |
| SCHEMBL10004388 | 0.87 | SMO (0.52) | SMO | |
| SCHEMBL10003362 | 0.87 | SMO (0.52) | SMOJAK2JAK1JAK3KCNH2 | |
| SCHEMBL10003233 | 0.87 | SMO (0.52) | SMOJAK2JAK1JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8486965-B2 | Pyrrolo[2,3-b]pyridine derivative and use thereof for treatment of cancer | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-07-16 | — | — | US | disclosed |
| US-8486965-B2 | Pyrrolo[2,3-b]pyridine derivative and use thereof for treatment of cancer | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-07-16 | — | — | US | disclosed |
| US-20120220569-A1 | FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-08-30 | — | — | US | disclosed |
| US-20120220569-A1 | FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220569-A1 | FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF | SMO, GLI1, SHH | SMO 1/4885PDE10A 428/4885HPGDS 790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.